Navigation Links
Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
Date:10/10/2007

Clergy Statement and National HIV/AIDS Elimination Act

NEW YORK, Oct. 10 /PRNewswire/ -- In the spirit of our historic role of advancing prophetic social justice ministry, Black clergy are stepping forward to play a stronger leadership role in advocating for theologically sound HIV/AIDS public policy. Working with the National Black Leadership Commission on AIDS (NBLCA), we are determined to live up to the biblical mandate that calls us to be "the light of the world." With faithfulness to this calling, we must compassionately embrace those who are infected with and affected by HIV/AIDS. Through life-affirming ministry, we are committed to caring for the physical, mental and spiritual needs of all people in our communities whose lives are being devastated by this insidious disease.

Just as African American clergy fervently came together 50 years ago to fight for civil rights, we are banning together today to bring an end to HIV/AIDS and its potential to obliterate our community. To combat this plague, which is claiming five to seven thousand lives per day worldwide and is destroying Black families and killing Black men and women at a disproportionate rate of genocidal magnitude:

-- We will aggressively seek to have every person under the sphere of our

influence tested for HIV in order to know their status.

-- We will promote HIV/AIDS awareness to insure that all Black clergy

serving in our denominations and other congregations are equipped to

address issues related to this disease in a factual and scientifically

sound manner.

-- We will use the ABC/D model as a behavioral guideline for prevention

initiatives:

A ---- Abstain

B ---- Be Faithful

C ---- Use Condoms

D ---- Don't Engage In Risky Behavior

To ensure that we are jointly using our resources to influence and impact public policy, our proposed legislative
'/>"/>

SOURCE The National Conclave
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
11. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  A new global ... finds that a large majority of the general public ... (84%), a devastating disease that is responsible for 1.59 ... cancers combined 1,2,4 . The "Any One Any Lung" ... about the widespread impact of lung cancer, but also ...
(Date:11/18/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... receipt of approval from the U.S. Food and Drug ... IMPLANT ® Saline-filled Breast Implant for ... augmentation implants. The FDA approval of the IDEAL IMPLANT ... and data including a U.S. clinical trial that began ...
(Date:11/18/2014)... Tocagen Inc. today announced that ... free survival at six months for recurrent high grade ... FC, compared to published benchmarks. HGG includes glioblastoma, the ... The data were delivered in an oral presentation at the ... of the Society for Neuro-Oncology (SNO) by Tim ...
Breaking Medicine Technology:Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5
... May 16 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO.OB) ... Phase I Human Trials with its PulmoBind Molecular Imaging,technology ... The work will be carried out by the Pulmo ... is: "Phase I Study of the Use,of PulmoBind for ...
... -- Results demonstrating that TYKERB and trastuzumab ... survival (PFS), -- Combining TYKERB and trastuzumab ... HER2 receptor may create a more complete HER2 ... alone despite patients,previous treatment with multiple lines of ...
Cached Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... 18, 2014 Medicationdiscountcard.com's ... adding to the company's reputation for helping consumers ... blog has to offer at http://blog.medicationdiscountcard.com/ . ... information concerning the Affordable Care Act and the ... inform the public about a variety of prescription ...
(Date:11/18/2014)... Thompson HealthDay Reporter ... antibody drug could prove effective at lowering LDL ("bad") ... cholesterol-lowering statin medications. That,s the conclusion of a ... annual meeting in Chicago. The drug, alirocumab, outperformed ... used alternative to statins, Zetia, said lead researcher Dr. ...
(Date:11/18/2014)... (HealthDay News) -- Women who started smoking at a ... severe menstrual pain, a new study suggests. About ... smoking has been suspected as a risk factor for ... authors of the new study said. The researchers ... long-term study of women,s health in Australia. About 14 ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... from Shropshire and parts of Wales. Breast cancer patients from ... but Welsh women get it for free. // ,This ... to pay for Herceptin for early stage breast cancer sufferers ... the welsh as all Welsh Local Health Boards have agreed ...
... in the capital of Zagreb it was revealed that a dead ... flu virus. //, ,The location of the dead swan was ... weekend. Tests confirmed that the dead bird had contracted the H5 ... it was the lethal H5N1 strain would be released on Sunday ...
... simulated investment game, a study, intending to investigate ... working //collectively in a team, revealed stark observations ... conducted by the University of Erfurt team, found ... when ‘punishments’ became a form of motivation. Psychologists ...
... nations should be prepared to pledge more money to combat ... ,Western and Asian donors had pledged $1.9 billion ... flu and improve containment and prevention methods in 12 countries, ... spreading across the world through migratory birds, including infections in ...
... should avoid exposure to the fumes of solvents used ... and lacquers//, could give rise to allergies in young ... Germany's environmental agency. ,Pregnant women should leave ... stay clear of the work area altogether. ...
... has warned the nation's betel-nut chewers of the increased ... habits like smoking and drinking. ,According to ... National Health Research Institute when betel nut chewing was ... cancer of the esophagus was about 195 times higher ...
Cached Medicine News:Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2Health News:Motivation Yardstick: Rewards or Punishment? Discover the Superior Performance Trigger 2Health News:Cancer Risks for Betel Nut Chewers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: